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Several investigators have reported that tumor necrosis factor (TNF) can alter the production of plasminogen activator type-1 (PAI-1) and plasminogen activators (PAS) by endothelial cells in vitro. We have examined the in vivo effects of recombinant human TNF administration on fibrinolysis as assessed by parameters in plasma during a 24-hour period of continuous TNF infusion to 17 cancer patients with active disease. The plasma levels of PA1 activity increased sevenfold after 3 and 24 hours of TNF infusion. This was the result of an increase of PAI-1 antigen; PAI-2 antigen was not detectable. Plasma concentrations of tissue-type PA (t-PA) antigen increased twofold to fivefold after 3 and 24 hours of TNF infusion, whereas urokinase-type PA antigen levels in plasma remained unaltered. After 3 hours of TNF infusion the plasma levels of a,-antiplasmin were slightly decreased, 5% on average, suggesting that fibrinolysis continued. After 24 hours of TNF infusion a highly significant increase in fibrin-plus H E FIBRINOLYTIC PROCESS in plasma is regu-T lated by plasminogen activators, particularly tissuetype plasminogen activator (t-PA) and plasminogen activator inhibitor(s), which are synthesized by the endothelium. The inflammatory mediators tumor necrosis factor (TNF), interleukin-1, and lymphotoxin have profound effects on endothelial cells and on their hemostatic properties. ' We and others2x3 have previously demonstrated that T N F increases the production of plasminogen activator inhibitor type-1 (PAI-1) by human endothelial cells in vitro, whereas t-PA production did not increase2 or even decrea~ed.~ In cultured human endothelial cells, T N F also induces the synthesis of urokinase-type plasminogen activator (u-PA), which is secreted predominantly a t the basolateral side of the cells.4 In addition to in vitro data, it was shown that injection of TNF in rats resulted in a marked increase in the plasma level of PA1 inhibitor activity.2s5 However, no further evaluation of the fibrinolytic process in rats on T N F administration has been made, partly due to the species specificity of the necessary reagents. fibrinogen-degradation products, and separately of fibrin degradation products and fibrinogen degradation products, was found. This indicates that fibrinolysis persisted, at least partly, in the presence of high levels of PA1 activity. Whereas PAI-1 production increased, t-PA production by human endothelial cells in vitro remains unaltered or even decreases on TNF addition. It has been shown previously that TNF infusion in our patients results in thrombin and fibrin generation. Therefore, it is possible that thrombin, not TNF, is the actual stimulus for t-PA production in our patients. We speculate that fibrin is formed during TNF infusions and that plasmin is generated by t-PA action immediately on the initial formation of (soluble) fibrin molecules. Such a process may explain the generation of degradation products of both fibrin and fibrinogen during infusion of TNF in patients. 0 1990 by The American Society of Hematology.
Recently, several clinical trials have been conducted to evaluate the possible use of human recombinant TNF in the treatment of malignant
The effect of T N F on coagulation was extensively evaluated during one of these phase I clinical studies using TNF in patients with active malignancies.' During infusion of T N F an increased rate of thrombin generation and fibrin formation was observed. In the same plasma samples we have now examined various parameters of the fibrinolytic system. In addition to the plasma concentration of the plasminogen activators and their inhibitors, we assayed consumption of a,-antiplasmin and the generation of fibrin-and fibrinogen-degradation products to evaluate the fibrinolytic process during infusion of TNF in humans.
MATERIALS AND METHODS
Patients with histologic evidence of carcinoma, lymphoma, or sarcoma enrolled in phase I trials of recombinant human T N F at the Dana-Farber Cancer Institute (Boston, MA) were studied.',* The drug was administered by continuous intravenous (IV) infusion via a peripheral arm vein. Indomethacin (50 mg) was administered orally every 6 hours for four doses starting 12 hours before each infusion. Normal clinical measures of hepatic (total bilirubin i 1.5 mg/dL, SGOT i 60 IU/L) and renal function (serum creatinine < 1.5 mg/dL) were required before treatment. Specimen collection and informed consent procedures were approved by the Institute's Human Protection Committee.
Recombinant human T N F was supplied by Asahi Chemical Industry America, Inc (New York, NY). The specific activity of this preparation is 2.3 x lo6 U/mg protein. T N F preparations contained less than 100 pg of endotoxin/106 U as measured by the Limulus test." The drug was diluted with normal saline to a total volume of 100 to 300 mL for IV administration.
Venipunctures were performed automatically with 19-or 21-gauge butterfly infusion sets on the arm contralateral to that receiving the T N F infusion. A two-syringe technique was used and blood samples were drawn Patient selection and therapy.
Drug formulation.
Collection and processing of blood samples. into plastic syringes preloaded with 3.8% (wt/vol) sodium citrate; the ratio of anticoagulant to blood was 0.1 to 0.9 (vol/vol). After collection of the blood samples, plasma fractions were obtained by centrifugation at 4OC for 30 minutes at 1,600g and stored at -8OOC before use.
A normal plasma pool was made by admixing equal volumes of plasma of 24 control subjects. This control population consisted of healthy laboratory personnel between the ages 20 and 50 years, with a negative history of bleeding and thrombosis, and who were not taking any medications at the time of sample collection.
Assays. All assays have been performed in duplicate or in triplicate.
t-PA antigen concentration in the plasmas was measured by enzyme immunoassay (EIA) (IMULYSE) purchased from Biopool (UmeA, Sweden) according to the manufacturer's description. In this assay, t-PA and t-PA inhibitor complexes are claimed to be detected with similar efficiency.
The level of u-PA antigen was determined with an enzyme-linked immunosorbent assay (ELISA) for urokinase as described by
Binnema et al." The assay measures the inactive proenzyme single-chain u-PA (sc-u-PA), the active two-chain u-PA (tc-u-PA), and u-PA:PA inhibitor complexes with equal efficiency.
The plasmin-activatable u-PA activity (sc-u-PA) and active tc-u-PA were measured by a biologic immunoassay (BIA) as previously described." PA1 activity was measured by the quantitative assay for plasminogen activator activity as described by Verheijen et al.I3 It was determined by titration, with increasing amounts of t-PA, of a fixed volume of plasma or pooled plasma. The amount of PA inhibitor activity was calculated from the intersection of the asymptote of the titration curve with the X-axis. In all experiments this asymptote ran parallel to the control titration curve.
The plasma levels of PAI-1 antigen were determined by an EIA (IMULYSE, Biopool). According to the manufacturer, this assay determines mainly the unbound PAI-1 (both latent and active), whereas the t-PA:PAI-1 complex is recovered with about IO-fold lower efficiency. The plasma concentrations of PAL2 antigen were determined by enzyme immunoassay (TintElize PAI-2; Biopool).
In addition to the assessment of the total amount of degradation use only. products from fibrin and fibrinogen (TDPs), specific determinations of fibrinogen-degradation products (FgDPs) and fibrin-degradation products (FbDPs) were made. All three assays are sandwich EIAs (Organon-Teknika, Turnhout, Belgium) based on a monoclonalcatching antibody (FDP-14) against a neoantigenic determinant in the E-domain of degradation products of fibrin and fibrinogen, but not with the intact parent molecule^.'^ For the specific assay of FgDPs, a horseradish peroxidase (HRP)-conjugated monoclonal antibody (MoAb) ('Y 18'14), reactive with covalently bound fibrinopeptide A,I5 was used as tagging antibody. For the specific FbDP assay an HRP-conjugate of an MoAb against the fibrin D-domain ("DD13") was used as the tagging antibody.16 For the TDP assay a mixture of monoclonals Y 18 and DD13 (both HRP conjugated) was used as a tagging antibody." These tests are not influenced by the rheumatoid factor; normal values for TDPs, FgDPs, and FbDPs in plasma are below 0.5 pg/mL." a,-Antiplasmin activity was assayed spectroph~tometrically.'~ The presence of plasmin-a,-antiplasmin complexes was evaluated by crossed immunoelectrophoresis in 1% agarose gels, as previously described.*' The first dimension was run for 3 hours at 100 V; the second overnight at 100 V at about 10°C. The a,-antiplasmin rabbit antiserum was purchased from Diagnostica Stago (Asnibres, France). The detection limit was estimated by addition of plasmin to plasma; it was 2.5% of conversion of a,-antiplasmin in plasmin-antiplasmin (PAP) complex.
von Willebrand factor (vWF) was determined by ELISA as described previously."
Statistical evaluation. The data are expressed as the mean + SD; the significance was analyzed using the Student's t-test for paired data.
RESULTS
The changes in the plasma levels of the plasminogen activators t-PA and u-PA, and their inhibitors PAI-1 and PAI-2 during infusion of T N F are shown for three patients in Fig 1. After a 3-hour infusion of T N F an increase in the circulating PA1 activity was observed. During continuation of the infusion over a 24-hour period PA1 activity further increased in all but one of the patients (seven of eight). As is shown in Fig lA, this PA1 activity parallels the increase in PAI-1 antigen; no PAI-2 antigen was detectable. During the T N F infusion there was a rapid increase in the circulating t-PA antigen concentration, which was in all cases higher after 3 hours of infusion than after 24 hours (Fig 1B) . No significant effect on the u-PA concentration in plasma was observed. Because rapidly induced increases in plasma t-PA concentration are commonly accompanied by increases in vWF, we also determined the vWF concentration. Plasma levels of vWF after 3 and 24 hours of TNF infusion in these three patients were 185% f 43% and 281% f 19%, respectively, of the preinfusion concentration (mean f SD).
In another patient a sample was obtained a t 75 minutes after the onset of the T N F infusion. At this time point t-PA antigen had increased fourfold (Fig 2) , and vWF concentration was elevated 1.7-fold (not shown). Spontaneous fibrinolytic activity, but no PA1 activity, was detected in the plasma (Fig 2) . No increase in PAI-1 antigen was observed at this time point, indicating that the increase in t-PA preceded the rise in PAI-1. After a 24-hour infusion of TNF the level of PAI-1 exceeded that of t-PA, and an elevated PA1 activity was found. The data of 17 patients receiving T N F concentrations, which varied from 1 x lo5 to 14 x lo5 U TNF/m2/24 h, are summarized in Tables 1 and 2 . In all these patients it has been established that during T N F infusion there was evidence of thrombin generation, as indicated by circulating F,+,, and fibrin formation, as indicated by fibrinopeptide A generation.' After 3 and 24 hours, both t-PA antigen and PA1 activity were significantly elevated. The plasma concentrations of overall u-PA antigen (Tables 1 and 2) and prourokinase (not shown) were not significantly altered.
The increase of both t-PA and PA1 activity presented an opportunity of evaluating whether, under such conditions, fibrinolysis still occurs. To that end, we measured the circulating concentrations of the total of TDPs, FbDPs and FgDPs by highly sensitive immunoassays. After the 24-hour T N F infusion a marked increase could be demonstrated not only in FbDPs but also in FgDPs. Hence, fibrinolysis must have continued during this infusion period. The levels of fibrin(ogen) degradation products showed a tendency to increase also at 3 hours of infusion, but this increase was not statistically significant. The increase in fibrin(ogen) degradation products was seen both in patients with ongoing fibrinolysis, as estimated from elevated levels of FbDPs and FgDPs a t the start of the TNF infusion, and in patients with normal levels of FbDPs and FgDPs before the T N F infusion (Table   As a patients receiving 3 x lo5 to 12 x lo5 U/m2/24 h TNF were investigated. In two patients, who had u-PA antigen levels of 8 and 16 ng/mL and t-PA antigen levels of 11 and 13 ng/mL, the basal level of a,-antiplasmin was 67% to 68% of the value of pooled human plasma. The range of a2-antiplasmin activity in normal individuals is 85% to 12095, which suggested that in these two patients fibrinolysis already occurred before the start of TNF infusion. In the other seven patients the basal a,-antiplasmin levels ranged from 86% to 113% (102% f 9%, mean f SD) of pooled human plasma. After 3 hours of TNF infusion, a,-antiplasmin levels decreased slightly in seven of the nine patients and became on the average 95% f 6% of the preinfusion values (P < .OS). After 24 hours a decrease in a,-antiplasmin concentration was measured in seven of the nine patients and an increase by 15% in one patient; on average the 24-hour values were 94% * 12% of the preinfusion value. Plasma samples obtained after 3 hours of TNF infusion were examined for PAP-complexes by crossed immunoelectrophoresis. In five of seven patients with normal preinfusion values of a,-antiplasmin, a small amount of PAP complexes was detectable (not shown). In the two patients with decreased preinfusion a,-antiplasmin levels, no PAPcomplexes could be demonstrated at this time point. This suggests that no intensive fibrinolytic activity occurred after 3 hours of TNF infusion and that the PAP-complexes were rapidly cleared.
DISCUSSION
In the present report we demonstrate that the plasma levels of both t-PA and PAI-1 increase on infusion of TNF in patients, whereas the plasma levels of u-PA and PAI-2 are not affected. Concomitantly, the levels of FbDPs and FgDPs increase in the circulating blood.
The increase in PA1 activity was totally accounted for by PAI-1. TNF induces PAI-1 messenger RNA and protein in human endothelial cells in vitro.'v3 In a previous study we indicated that the increased amount of PAI-1 induced by TNF is predominantly produced by the vascular tree, in particular the endothelium, and is not produced by blood platelets or hepatocytes., t-PA is synthesized in endothelial cells in vivo2' as well as in ~itro,'~,'~ but in contrast to PAI-1, the in vitro synthesis of t-PA is not increased by TNF; it remains unaffected or even decrease^.'.^ Bauer et aI9 reported that infusion of TNF induces thrombin generation in the patients that we have studied. Thrombin is an active stimulator of both acute release of t-PA in vascular bedsz5 and of the synthesis of t-PA by human endothelial cells in ~itro.'~,'' We propose that thrombin generation may be the actual trigger for the increased level of t-PA during infusion of TNF. During the first hour@) the t-PA level would be predominantly increased by the "acute" release mechanism, whereas prolonged TNF infusion increased the t-PA level by de novo synthesis. Additional experiments with inhibitors of factor Xa and thrombin are necessary to verify this proposed mechanism.
The response of t-PA and PAI-1 to T N F infusion in our patients is similar to the response of these parameters to infusion of endotoxin in healthy volunteers.28 This suggests that the observed effects do not merely reflect that pieces of the vascular bed in the patients have altered characteristics, caused by the underlying malignancy, but rather that our observations are representative of the normal vascular system. In the study of Suffredini et a12' blood samples were taken every hour over a 5-hour period. It was demonstrated that the increase of the t-PA level preceded the rise in circulating PA1 activity. Results in one of our patients (Fig  2) suggest that the same occurs during T N F infusion. In addition, Suffredini et aI2' reported consumption of a*-antiplasmin (8%) m d the generation of PAP-complexes. Consumption of a,-antiplasmin (5%) and formation of a small amount of PAP-complexes was detected during T N F infusion in the majority of our patients. At 24 hours of infusion of TNF, the level of a,-antiplasmin may increase again by an acute phase response, but this response is not likely to occur within 3 hours. The limited consumption of a,-antiplasmin in both studies suggests that the fibrinolytic process is active, but a t a moderate level. This may be coupled to the rate of fibrin formation.
The concomitant elevation of both t-PA antigen and PAL 1 antigen, resulting in an elevated plasma PA1 activity, was observed after continuation of the TNF infusion for 3 hours or more. To evaluate whether the fibrinolytic process is indeed active under these circumstances we have used three very sensitive new assays for the determination of FbDPs and FgDPs. Within 3 and 24 hours of TNF infusion there was a marked increase in circulating FbDPs, both in the patients that had no detectable fibrin(ogen) degradation products and in those that showed ongoing fibrinolysis a t the start of the infusion. This indicates that fibrinolysis is indeed active. It does not exclude the possibility that the increase in PAI-1 level retards the process.
Not only do the levels of FbDPs increase, but there also is a parallel increase in the levels of FgDPs amounting to about 30% of the level of FbDPs. This increase in FgDPs was not expected here because no change in u-PA is seen. Several possibilities may explain the generation of FgDPs. Firstly, a t the initial generation of fibrin by thrombin, fibrin monomer is formed, which remains soluble in complex with fibrinogen. t-PA can bind to this fibrin monomer and activate plasmino- T h e plasmin that is consequently generated may also degrade fibrinogen (in the complex). This mechanism can only occur when fibrin is generated diffusely. Similar findings have been reported in diffuse intravascular c o a g u l a t i~n . "~~~~ Secondly, the involvement of another protease that degrades fibrinogen during TNF infusion cannot be excluded a priori.
In Fig 3 we have summarized the suggested events that take place during TNF infusion.
